Atara Biotherapeutics (NASDAQ:ATRA)‘s stock had its “buy” rating reissued by William Blair in a research report issued on Thursday, TipRanks reports.
Several other research firms have also recently commented on ATRA. ValuEngine cut Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Friday. Cowen reissued a “buy” rating on shares of Atara Biotherapeutics in a research note on Tuesday, February 26th. BidaskClub cut Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, February 22nd. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, April 30th. Finally, Mizuho started coverage on Atara Biotherapeutics in a research note on Tuesday, January 22nd. They set a “buy” rating and a $62.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $43.33.
Shares of NASDAQ ATRA traded down $0.18 during trading on Thursday, reaching $23.99. The stock had a trading volume of 429,600 shares, compared to its average volume of 560,288. Atara Biotherapeutics has a fifty-two week low of $23.58 and a fifty-two week high of $54.45. The company has a current ratio of 9.96, a quick ratio of 9.96 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $1.15 billion, a PE ratio of -4.55 and a beta of 2.11.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.44) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.48) by $0.04. On average, equities analysts predict that Atara Biotherapeutics will post -5.69 earnings per share for the current year.
In related news, insider Joe Newell sold 1,500 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $39.96, for a total transaction of $59,940.00. Following the completion of the transaction, the insider now directly owns 63,646 shares of the company’s stock, valued at approximately $2,543,294.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Isaac E. Ciechanover sold 7,800 shares of the business’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $24.61, for a total value of $191,958.00. Following the transaction, the chief executive officer now directly owns 332,243 shares of the company’s stock, valued at $8,176,500.23. The disclosure for this sale can be found here. Insiders have sold a total of 129,990 shares of company stock valued at $4,678,666 over the last three months. 10.60% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Manchester Capital Management LLC purchased a new stake in Atara Biotherapeutics during the 1st quarter worth about $56,000. Quantamental Technologies LLC purchased a new stake in Atara Biotherapeutics during the 4th quarter worth about $62,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in Atara Biotherapeutics by 31.7% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 4,042 shares of the biotechnology company’s stock worth $115,000 after buying an additional 974 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in Atara Biotherapeutics during the 4th quarter worth about $128,000. Finally, Coastal Investment Advisors Inc. purchased a new stake in Atara Biotherapeutics during the 1st quarter worth about $142,000.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Read More: What is the Stochastic Momentum Index (SMI)?
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.